Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.67 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.67 |
| ▸ | TERF2 | Q15554 | 2/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.40 |
| ▸ | MC4R | P32245 | 2/20 | 0.39 |
| ▸ | MC1R | Q01726 | 2/20 | 0.39 |
| ▸ | IDE | P14735 | 1/20 | 0.39 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.38 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25455642 | 0.92 | KDM1A (0.77) | KDM1ARCOR1TERF2 | |
| SCHEMBL25455822 | 0.92 | KDM1A (0.77) | KDM1ARCOR1TERF2 | |
| SCHEMBL20366251 | 0.92 | KDM1A (0.77) | KDM1ARCOR1TERF2 | |
| SCHEMBL25466596 | 0.92 | KDM1A (0.77) | KDM1ARCOR1TERF2 | |
| SCHEMBL25465478 | 0.92 | KDM1A (0.69) | KDM1ARCOR1TERF2PSMB5PSMB2 | |
| SCHEMBL24270420 | 0.90 | KDM1A (0.70) | KDM1ARCOR1TERF2PSMB5PSMB2 | |
| SCHEMBL22677698 | 0.90 | KDM1A (0.68) | KDM1ARCOR1TERF2PSMB5PSMB2 | |
| SCHEMBL22677633 | 0.90 | KDM1A (0.68) | KDM1ARCOR1TERF2PSMB5PSMB2 | |
| SCHEMBL22677681 | 0.90 | KDM1A (0.70) | KDM1ARCOR1TERF2PSMB5PSMB2 | |
| SCHEMBL24270410 | 0.90 | KDM1A (0.70) | KDM1ARCOR1TERF2PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | KDM1A 3592/4885RCOR1 4682/4885TERF2 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.